艾迪药业: 艾迪药业董事会薪酬与考核委员会关于2025年股票期权激励计划首次授予激励对象名单的核查意见（授予日）

Core Points - The company has conducted a review of the initial grant list for the 2025 stock option incentive plan, confirming that it aligns with the approved draft by the second extraordinary general meeting of shareholders in 2025 [1][2] - A total of 8.96 million stock options will be granted to 43 incentive recipients, with an exercise price set at 13.01 yuan per option, effective from August 14, 2025 [2] Summary by Categories Incentive Recipients - The list of incentive recipients is consistent with the conditions outlined in the company's 2025 stock option incentive plan draft [1][2] - The recipients meet the qualifications as per relevant laws, regulations, and the company's articles of association [2] Compliance and Regulations - The review confirms that none of the recipients fall under categories that would disqualify them from receiving stock options, such as being deemed inappropriate by the securities exchange or regulatory authorities within the last 12 months [1][2] - The review adheres to the stipulations set forth in the Company Law, Securities Law, and other regulatory frameworks [1][2]